High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects

Deborah Watson-Jones, Kathy Baisley, Joelle Brown, Bazil Kavishe, Aura Andreasen, John Changalucha, Philippe Mayaud, Saidi Kapiga, Balthazar Gumodoka, Richard J Hayes, Silvia de Sanjosé, Deborah Watson-Jones, Kathy Baisley, Joelle Brown, Bazil Kavishe, Aura Andreasen, John Changalucha, Philippe Mayaud, Saidi Kapiga, Balthazar Gumodoka, Richard J Hayes, Silvia de Sanjosé

Abstract

Objectives: We measured the prevalence and incidence of human papillomavirus (HPV) infection in young female subjects recruited for a safety and immunogenicity trial of the bivalent HPV-16/18 vaccine in Tanzania.

Methods: Healthy HIV negative female subjects aged 10-25 years were enrolled and randomised (2:1) to receive HPV-16/18 vaccine or placebo (Al(OH)3 control). At enrolment, if sexually active, genital specimens were collected for HPV DNA, other reproductive tract infections and cervical cytology. Subjects were followed to 12 months when HPV testing was repeated.

Results: In total 334 participants were enrolled; 221 and 113 in vaccine and control arms, respectively. At enrolment, 74% of 142 sexually active subjects had HPV infection of whom 69% had >1 genotype. Prevalent infections were HPV-45 (16%), HPV-53 (14%), HPV-16 (13%) and HPV-58 (13%). Only age was associated with prevalent HPV infection at enrolment. Among 23 girls who reported age at first sex as 1 year younger than their current age, 15 (65.2%) had HPV infection. Of 187 genotype-specific infections at enrolment, 51 (27%) were present at 12 months. Overall, 67% of 97 sexually active participants with results at enrolment and 12 months had a new HPV genotype at follow-up. Among HPV uninfected female subjects at enrolment, the incidence of any HPV infection was 76 per 100 person-years.

Conclusions: Among young women in Tanzania, HPV is highly prevalent and acquired soon after sexual debut. Early HPV vaccination is highly recommended in this population.

Keywords: AFRICA; HPV; SEROPREVALENCE.

Figures

Figure 1
Figure 1
Prevalence of human papillomavirus (HPV) by genotype in 117 sexually active girls at enrolment.

References

    1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–917
    1. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453–9
    1. Smith JS, Melendy A, Rana RK, et al. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008;43:S5–25, S25 e1–41
    1. Bruni L, Diaz M, Castellsague X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010;202:1789–99
    1. Watson-Jones D, Baisley K, Ponsiano R, et al. HPV vaccination in Tanzanian schoolgirls: cluster-randomised trial comparing two vaccine delivery strategies. J Infect Dis 2012;206:678–86
    1. Salif Sow P, Watson-Jones D, Kiviat N, et al. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomised trial in HIV-seronegative African females. J Infect Dis Published Online First: 13 Dec 2012. doi:10.1093/infdis/jis619
    1. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens—Part B: biological agents. Lancet Oncol 2009;10:321–2
    1. Ndiaye C, Alemany L, Ndiaye N, et al. Human papillomavirus distribution in invasive cervical carcinoma in sub-Saharan Africa: could HIV explain the differences? Trop Med Int Health. Published Online First: 29 Oct 2012. doi:10.1111/tmi.12004.
    1. Sangwa-Lugoma G, Ramanakumar AV, Mahmud S, et al. Prevalence and determinants of high-risk human papillomavirus infection in women from a Sub-Saharan African community. Sex Transm Dis 2011;38:308–15
    1. Dartell M, Rasch V, Kahesa C, et al. Human papillomavirus prevalence and type distribution in 3603 HIV-positive and HIV-negative women in the general population of Tanzania: the PROTECT study. Sex Transm Dis 2012;39:201–8
    1. Molano M, Posso H, Weiderpass E, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 2002;87:324–33
    1. Sargent A, Bailey A, Almonte M, et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer 2008:1704–9
    1. Louie KS, de Sanjose S, Mayaud P. Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review. Trop Med Int Health 2009;14:1287–302
    1. Clarke MA, Gage JC, Ajenifuja KO, et al. A population-based cross-sectional study of age-specific risk factors for high risk human papillomavirus prevalence in rural Nigeria. Infect Agent Cancer 2011;6:12.
    1. Asiimwe S, Whalen CC, Tisch DJ, et al. Prevalence and predictors of high-risk human papillomavirus infection in a population-based sample of women in rural Uganda. Int J STD AIDS 2008;19:605–10
    1. Bell MC, Schmidt-Grimminger D, Jacobsen C, et al. Risk factors for HPV infection among American Indian and White women in the Northern Plains. Gynecol Oncol 2011;121:532–6
    1. Maucort-Boulch D, Plummer M, Castle PE, et al. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer 2010;126:684–91
    1. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–8
    1. Banura C, Franceschi S, van Doorn LJ, et al. Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda. Int J Cancer 2008;123:2180–7
    1. Trottier H, Mahmud SM, Lindsay L, et al. Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. Cancer Epidemiol Biomarkers Prev 2009;18:854–62
    1. Insinga RP, Perez G, Wheeler CM, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev 2011;20:287–96
    1. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415–23
    1. Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003;158:486–94
    1. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048–56
    1. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927–35
    1. McDonald AC, Denny L, Wang C, et al. Distribution of high-risk human papillomavirus genotypes among HIV-negative women with and without cervical intraepithelial neoplasia in South Africa. PLoS ONE 2012;7:e44332.
    1. Nnko S, Boerma JT, Urassa M, et al. Secretive females or swaggering males? An assessment of the quality of sexual partnership reporting in rural Tanzania. Soc Sci Med 2004;59:299–310
    1. Langhaug LF, Cheung YB, Pascoe SJ, et al. How you ask really matters: randomised comparison of four sexual behaviour questionnaire delivery modes in Zimbabwean youth. Sex Transm Infect 2011;87:165–73
    1. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218–26
    1. In2eastafrica (accessed 21 Jul 2012).
    1. Winer RL, Feng Q, Hughes JP, et al. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008;197:279–82

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다